Bristol-Myers Squibb’s Blenoxane
FDA's Oncologic Drugs Advisory Committee on Sept. 23 will review a BMS supplemental NDA (50-443) for bleomycin sulfate as a sclerosing agent for the treatment of malignant pleural effusions (MPE) and for the prevention of recurrent pleural effusions. There currently is no approved therapy for MPE. The SNDA is literature- based and was filed by the company on June 11 ("The Pink Sheet" June 28, In Brief). Blenoxane currently is approved for the palliative treatment of squamous cell carcinoma, lymphomas and testicular carcinoma.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth